SCHEMBL30765893

SCHEMBL30765893

CSc1nnc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.33
KDM4E B2RXH2 5/20 0.33
LMNA P02545 5/20 0.33
NPSR1 Q6W5P4 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 3/20 0.32
MAPT P10636 3/20 0.32
MEN1 O00255 2/20 0.32
HPGD P15428 2/20 0.32
POLB P06746 2/20 0.32
ESR1 P03372 1/20 0.32
NPY1R P25929 1/20 0.32
NPY2R P49146 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
P2RX3 P56373 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765931 0.87 ALDH1A1 (0.37) ALDH1A1KDM4ELMNANPSR1JAK2
SCHEMBL30765941 0.87 ALDH1A1 (0.37) ALDH1A1KDM4ELMNANPSR1JAK2
SCHEMBL30765758 0.87 L3MBTL1 (0.40) ALDH1A1KDM4ELMNANPSR1TSHR
SCHEMBL30766068 0.84 GPR139 (0.34) ALDH1A1KDM4ELMNANPSR1KMT2A
SCHEMBL30765729 0.83 ALDH1A1 (0.38) ALDH1A1KDM4ELMNANPSR1JAK2
SCHEMBL30765944 0.82 ALDH1A1 (0.37) ALDH1A1KDM4ELMNANPSR1JAK2
SCHEMBL30765521 0.79 KMT2A (0.38) ALDH1A1KDM4ELMNANPSR1TSHR
SCHEMBL30765733 0.79 KMT2A (0.36) ALDH1A1KDM4ELMNANPSR1TSHR
SCHEMBL30765957 0.79 ALDH1A1 (0.38) ALDH1A1KDM4ELMNANPSR1JAK2
SCHEMBL30765712 0.78 LMNA (0.35) ALDH1A1KDM4ELMNANPSR1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed